12 completed, 2 terminated. 7 Phase 2, 4 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 7 |
| Phase 3 | 4 | Completed 2, Terminated 2 |
| Phase 1 | 3 | Completed 3 |
Follow Clearside Biomedical, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration CLS-AX, Aflibercept - Neovascular Age-related Macular Degeneration | Phase 2 | Completed | Clearside Biomedical, Inc. | 60 | 2023-05-31 | 2025-07-25 |
| Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study CLS-AX - Neovascular Age-related Macular Degeneration | Completed | Clearside Biomedical, Inc. | 15 | 2021-10-08 | 2024-03-04 | |
| Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD CLS-AX, Anti-VEGF - Neovascular Age-related Macular Degeneration | Phase 1 / Phase 2 | Completed | Clearside Biomedical, Inc. | 27 | 2020-12-15 | 2023-09-18 |
| Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO suprachoroidal CLS-TA, suprachoroidal sham, Lucentis or Avastin - Macular Edema, Retinal Vein Occlusion | Phase 3 | Terminated | Clearside Biomedical, Inc. | 325 | 2018-03-05 | 2021-04-23 |
| MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301 4 mg CLS-TA Suprachoriodal Injection, Sham procedure - Uveitis, Uveitis, Posterior | Completed | Clearside Biomedical, Inc. | 33 | 2017-12-13 | 2021-06-02 | |
| Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema IVT aflibercept, Sham SC, SC CLS-TA - Diabetic Macular Edema | Phase 2 | Completed | Clearside Biomedical, Inc. | 71 | 2017-07-11 | 2021-05-13 |
| Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis 4 mg CLS-TA Suprachoriodal Injection - Uveitis, Uveitis, Posterior | Phase 3 | Completed | Clearside Biomedical, Inc. | 38 | 2017-04-04 | 2021-06-23 |
| Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO suprachoroidal CLS-TA, suprachoroidal sham, IVT aflibercept - Macular Edema, Retinal Vein Occlusion | Phase 3 | Terminated | Clearside Biomedical, Inc. | 460 | 2017-01-31 | 2021-04-14 |
| Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema IVT Aflibercept, SC CLS-TA - Diabetic Macular Edema | Phase 1 / Phase 2 | Completed | Clearside Biomedical, Inc. | 20 | 2016-11-10 | 2021-05-13 |
| Retrospective Study of the Safety and Efficacy of Patients With RVO in Subjects Who Completed Parent Study CLS1003-201 Macular Edema, Retinal Vein Occlusion | Completed | Clearside Biomedical, Inc. | 20 | 2016-11-01 | 2019-12-20 | |
| Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis 4mg CLS-TA Suprachoriodal Injection, Sham Procedure - Uveitis, Uveitis, Posterior | Phase 3 | Completed | Clearside Biomedical, Inc. | 160 | 2015-11-17 | 2021-05-28 |
| Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO 4 mg CLS-TA, Sham, IVT aflibercept - Macular Edema, Retinal Vein Occlusion | Phase 2 | Completed | Clearside Biomedical, Inc. | 46 | 2015-01-01 | 2021-02-08 |
| Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis 4 mg CLS-TA, 0.8 mg CLS-TA - Uveitis, Macular Edema | Phase 2 | Completed | Clearside Biomedical, Inc. | 22 | 2014-10-01 | 2021-02-08 |
| Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis triamcinolone acetonide (Triesence®) - Uveitis, Intermediate Uveitis | Phase 1 / Phase 2 | Completed | Clearside Biomedical, Inc. | 11 | 2013-02-01 | 2021-02-21 |
Macular Edema (5) · Panuveitis (5) · Uveitis (5) · Uveitis, Intermediate (5) · Uveitis, Posterior (5) · Retinal Vein Occlusion (4) · Uveitis, Anterior (4) · Choroidal Effusions (3) · Diabetes Mellitus (2) · Diabetic Retinopathy (2) · Giant Cell Arteritis (1) · Inflammation (1) · Ophthalmia, Sympathetic (1)
Triamcinolone Acetonide (8) · aflibercept (6) · Adrenal Cortex Hormones (1) · Bevacizumab (1) · Ranibizumab (1) · Triamcinolone (1) · salicylhydroxamic acid (1)
United States (14) · India (4) · Australia (2) · Hungary (2) · Israel (2) · Austria (1) · Canada (1) · Denmark (1) · Italy (1) · New Zealand (1) · Philippines (1) · Poland (1) · Portugal (1) · Slovakia (1) · Spain (1)
Thomas Ciulla, MD (8) · Susan Coultas, PhD (3) · Thomas Ciulla, MD MBA (2) · Thomas Cuilla, MD, MBA (1)
PMID 36787524, PMID 36399237, PMID 27980877, PMID 34322164, PMID 34741564, PMID 36055922